CN Patent

CN103126994B — 含决奈达隆的固体药物组合物

Assigned to BEIJING HONGWAN PHARMACEUTICAL TECHNOLOGY Co Ltd · Expires 2017-03-29 · 9y expired

What this patent protects

本发明涉及一种口服固体药物组合物，其特征在于它含有具有抗心律不齐的决奈达隆，或一种其药学上可以接受的盐类作为活性成分，和一种药学上可以接受的多羟基醇，可选与一种或多种药物赋形剂结合。

USPTO Abstract

本发明涉及一种口服固体药物组合物，其特征在于它含有具有抗心律不齐的决奈达隆，或一种其药学上可以接受的盐类作为活性成分，和一种药学上可以接受的多羟基醇，可选与一种或多种药物赋形剂结合。

Drugs covered by this patent

Patent Metadata

Patent number
CN103126994B
Jurisdiction
CN
Classification
—
Expires
2017-03-29
Drug substance claim
No
Drug product claim
No
Assignee
BEIJING HONGWAN PHARMACEUTICAL TECHNOLOGY Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.